Parkin-deficient Mice Exhibit Nigrostriatal Deficits but Not Loss of Dopaminergic Neurons
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
Loss-of-function mutations in parkin are the major cause of early-onset familial Parkinson's disease. To investigate the pathogenic mechanism by which loss of parkin function causes Parkinson's disease, we generated a mouse model bearing a germline disruption in parkin. Parkin-/- mice are viable and exhibit grossly normal brain morphology. Quantitative in vivo microdialysis revealed an increase in extracellular dopamine concentration in the striatum of parkin-/- mice. Intracellular recordings of medium-sized striatal spiny neurons showed that greater currents are required to induce synaptic responses, suggesting a reduction in synaptic excitability in the absence of parkin. Furthermore, parkin-/- mice exhibit deficits in behavioral paradigms sensitive to dysfunction of the nigrostriatal pathway. The number of dopaminergic neurons in the substantia nigra of parkin-/- mice, however, is normal up to the age of 24 months, in contrast to the substantial loss of nigral neurons characteristic of Parkinson's disease. Steady-state levels of CDCrel-1, synphilin-1, and alpha-synuclein, which were identified previously as substrates of the E3 ubiquitin ligase activity of parkin, are unaltered in parkin-/- brains. Together these findings provide the first evidence for a novel role of parkin in dopamine regulation and nigrostriatal function, and a non-essential role of parkin in the survival of nigral neurons in mice.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Importantly, parkin-deficient mice and mice expressing a dominant negative form of Nrdp1 are not reported to have significant neurodegenerative disease171819.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“The lack of reported neurodegeneration in parkin-deficient and Nrdp1 mutant mice171819 makes it unlikely that this interaction explains our finding of neurodegeneration in Clec16a mutant mice.”
From Clec16a is Critical for Autolysosome Function and Purkinje Cell Survival (2016) · cites this paper as [18]
In the citing paper
“Although PINK1 (McWilliams et al, 2018) and PRKN (Goldberg et al, 2003; Perez & Palmiter, 2005) deficiency do not elicit major defects under baseline conditions, defective striatal neural plasticity is observed in prkn− / − mice (Kitada et al, 2009).”
From Autophagy in major human diseases (2021) · cites this paper as Goldberg et al, 2003
Citations
Cites
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The unbiased estimation of number and sizes of arbitrary particles using the disector
Sterio, D. C. (1984) · Journal of Microscopy · doi:10.1111/j.1365-2818.1984.tb02501.x · Cited by 2,519
Familial Parkinson disease gene product, parkin, is a ubiquitin-protein ligase
Shimura, H., Hattori, N., Kubo, S.-I., Mizuno, Y., Asakawa, S., Minoshima, S., Shimizu, N., Iwai, K., Chiba, T., Tanaka, K., et al. (2000) · Nature Genetics · doi:10.1038/77060 · Cited by 2,024
Masliah, E., Rockenstein, E., Veinbergs, I., Mallory, M., Hashimoto, M., Takeda, A., Sagara, Y., Sisk, A., & Mucke, L. (2000) · Science · doi:10.1126/science.287.5456.1265 · Cited by 1,765
Dunham, N. W., & Miya, T. S. (1957) · Journal of the American Pharmaceutical Association (Scientific ed.) · doi:10.1002/jps.3030460322 · Cited by 1,716
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
Schallert, T., Fleming, S. M., Leasure, J. L., Tillerson, J. L., & Bland, S. T. (2000) · Neuropharmacology · doi:10.1016/s0028-3908(00)00005-8 · Cited by 1,354
Self-citationNeuronal α-Synucleinopathy with Severe Movement Disorder in Mice Expressing A53T Human α-Synuclein
Giasson, B. I., Duda, J. E., Quinn, S. M., Zhang, B., Trojanowski, J. Q., & Lee, V. M.-Y. (2002) · Neuron · doi:10.1016/s0896-6273(02)00682-7 · Cited by 1,266
Research works printed but not linked: 4
- Tanner, 1990, Neurology, 40, 17
- Parsons, 1994, Crit. Rev. Neurobiol., 8, 189
- Walsh, 1992, J. Pharmacol. Exp. Ther., 263, 617
- Schallert, 1988, Vol. 515, 108
Cited by
Items 101–200 of 913
Sriram, S. R., Li, X., Ko, H. S., Chung, K. K. K., Wong, E., Lim, K. L., Dawson, V. L., & Dawson, T. M. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi292 · Cited by 223
No Parkin Zone: Mitophagy without Parkin
Villa, E., Marchetti, S., & Ricci, J.-E. (2018) · Trends in Cell Biology · doi:10.1016/j.tcb.2018.07.004 · Cited by 221
BNIP3L/NIX-mediated mitophagy: molecular mechanisms and implications for human disease
Li, Y., Zheng, W., Lu, Y., Zheng, Y., Pan, L., Wu, X., Yuan, Y., Shen, Z., Ma, S., Zhang, X., et al. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04469-y · Cited by 219
“In the case of neurodegenerative diseases such as Parkinson’s and ALS, BNIP3L accelerated disease progression [59, 122, 127].”
BackgroundPhenotypic characterization of recessive gene knockout rat models of Parkinson's disease
Dave, K. D., De Silva, S., Sheth, N. P., Ramboz, S., Beck, M. J., Quang, C., Switzer, R. C., Ahmad, S. O., Sunkin, S. M., Walker, D., et al. (2014) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.06.009 · Cited by 222
“3C) indicating that this transcript was also destabilized, but not completely, consistent with Parkin KO mice (Goldberg et al., 2003).”
InfluentialSelf-citationPathogenic mutations in Parkinson disease
Tan, E.-K., & Skipper, L. M. (2007) · Human Mutation · doi:10.1002/humu.20507 · Cited by 223
“These mice do not suffer nigral neuronal degeneration or clinical manifestations of parkinsonism, save for subtle behavior and glutaminergic transmission alterations [Goldberg et al., 2003; Itier et al., 2003] and reduced numbers of noradrenergic neurons in the locus ceruleus were reported in one strain [von Coelln et…”
BackgroundParkin as a tumor suppressor gene for hepatocellular carcinoma
Fujiwara, M., Marusawa, H., Wang, H.-Q., Iwai, A., Ikeuchi, K., Imai, Y., Kataoka, A., Nukina, N., Takahashi, R., & Chiba, T. (2008) · Oncogene · doi:10.1038/onc.2008.199 · Cited by 218
“Several other groups independently generated parkin / mice with various targeted deletions of the parkin gene (Goldberg et al., 2003; Itier et al., 2003; Palacino et al., 2004; Von Coelln et al., 2004; Perez and Palmiter, 2005).”
BackgroundResultInfluentialTong, Y., Giaime, E., Yamaguchi, H., Ichimura, T., Liu, Y., Si, H., Cai, H., Bonventre, J. V., & Shen, J. (2012) · Molecular Neurodegeneration · doi:10.1186/1750-1326-7-2 · Cited by 214
“Similar to other PD genetic mouse models, such as a-synuclein transgenic [12-14], parkin-/- [15,16], DJ-1-/- [17,18], PINK1-/- [19,20], and LRRK2 transgenic and knockin mice [21-25], LRRK2-/brains did not develop overt dopaminergic degeneration [26].”
ResultSelf-citationUbiquitin–proteasome system and Parkinson's disease
Olanow, C. W., & McNaught, K. S. P. (2006) · Movement Disorders · doi:10.1002/mds.21013 · Cited by 212
da Costa, C. A., Sunyach, C., Giaime, E., West, A., Corti, O., Brice, A., Safe, S., Abou-Sleiman, P. M., Wood, N. W., Takahashi, H., et al. (2009) · Nature Cell Biology · doi:10.1038/ncb1981 · Cited by 212
“Parkin knockout murine brains have been described recently 29 .”
Self-citationParkin is a lipid-responsive regulator of fat uptake in mice and mutant human cells
Kim, K.-Y., Stevens, M. V., Akter, M. H., Rusk, S. E., Huang, R. J., Cohen, A., Noguchi, A., Springer, D., Bocharov, A. V., Eggerman, T. L., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci44736 · Cited by 211
Generation and characterization of Dyt1 ΔGAG knock-in mouse as a model for early-onset dystonia
Dang, M. T., Yokoi, F., McNaught, K. S. P., Jengelley, T.-A., Jackson, T., Li, J., & Li, Y. (2005) · Experimental Neurology · doi:10.1016/j.expneurol.2005.08.025 · Cited by 210
Mitochondrial and Cell Death Mechanisms in Neurodegenerative Diseases
Martin, L. J. (2010) · Pharmaceuticals · doi:10.3390/ph3040839 · Cited by 206
“However, parkin mice exhibit some evidence of dopaminergic presynaptic dysfunction in striatum and possible deficits in behavioral tests indicative of nigrostriatal dysfunction [382], although this finding has not been confirmed in another mouse line [383].”
BackgroundPINK1 Primes Parkin-Mediated Ubiquitination of PARIS in Dopaminergic Neuronal Survival
Lee, Y., Stevens, D. A., Kang, S.-U., Jiang, H., Lee, Y.-I., Ko, H. S., Scarffe, L. A., Umanah, G. E., Kang, H., Ham, S., et al. (2017) · Cell Reports · doi:10.1016/j.celrep.2016.12.090 · Cited by 206
“Dopamine neurons do not degenerate in germline parkin knockout mice (Goldberg et al., 2003; Itier et al., 2003; Von Coelln et al., 2004b).”
Impaired dopamine release in Parkinson’s disease
Cramb, K. M. L., Beccano-Kelly, D., Cragg, S. J., & Wade-Martins, R. (2023) · Brain · doi:10.1093/brain/awad064 · Cited by 207
“Despite this, some reports observed motor phenotypes in the absence of cell death in Parkinson’s disease animal models.(38,40,58,61,66,143) This finding presents a critical challenge to the definition of Parkinson’s disease.”
BackgroundResultReview: Parkinson's disease: from synaptic loss to connectome dysfunction
Bellucci, A., Mercuri, N. B., Venneri, A., Faustini, G., Longhena, F., Pizzi, M., Missale, C., & Spano, P. (2016) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12297 · Cited by 206
Behavioral phenotyping of mouse models of Parkinson's disease
Taylor, T. N., Greene, J. G., & Miller, G. W. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.004 · Cited by 199
“Parkin ↔locomotion [93,126] ↔rotarod [93,126], ↔ pole test, challenging beam [126,127] ↔ stride length, grid test [127] ↔ catalepsy test [127]”
BackgroundMitochondria as Cellular and Organismal Signaling Hubs
Shen, K., Pender, C. L., Bar-Ziv, R., Zhang, H., Wickham, K., Willey, E., Durieux, J., Ahmad, Q., & Dillin, A. (2022) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev-cellbio-120420-015303 · Cited by 194
Alpha-synuclein and transgenic mouse models
Fernagut, P.-O., & Chesselet, M.-F. (2004) · Neurobiology of Disease · doi:10.1016/j.nbd.2004.07.001 · Cited by 200
“, 2003), in parkin-deficient mice (Goldberg et al., 2003), or reviewed in the MPTP mouse model of PD (Sedelis et al.”
BackgroundSelf-citationRomanello, V., & Sandri, M. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03662-0 · Cited by 197
Antioxidants protect PINK1 -dependent dopaminergic neurons in Drosophila
Wang, D., Qian, L., Xiong, H., Liu, J., Neckameyer, W. S., Oldham, S., Xia, K., Wang, J., Bodmer, R., & Zhang, Z. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0604661103 · Cited by 197
Neurotoxic in vivo models of Parkinson’s disease
Cannon, J. R., & Greenamyre, J. T. (2010) · Progress in Brain Research · doi:10.1016/s0079-6123(10)84002-6 · Cited by 191
Animal models of Parkinson's disease
Jackson-Lewis, V., Blesa, J., & Przedborski, S. (2012) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(11)70057-8 · Cited by 191
Modelling of Parkinson's disease in mice
Chesselet, M.-F., & Richter, F. (2011) · The Lancet Neurology · doi:10.1016/s1474-4422(11)70227-7 · Cited by 192
Self-citationChen, L., Xie, Z., Turkson, S., & Zhuang, X. (2015) · The Journal of Neuroscience · doi:10.1523/jneurosci.0089-14.2015 · Cited by 187
Parkin genetics: one model for Parkinson's disease
Mata, I. F. (2004) · Human Molecular Genetics · doi:10.1093/hmg/ddh089 · Cited by 188
“However, both models do exhibit nigrostriatal deficits, with subtle behavioral phenotypes which may represent a relatively early stage of the degenerative process (67,68).”
BackgroundDopamine in neurotoxicity and neuroprotection: what do D2 receptors have to do with it?
Bozzi, Y., & Borrelli, E. (2006) · Trends in Neurosciences · doi:10.1016/j.tins.2006.01.002 · Cited by 187
Mitochondrial function in development and disease
Rossmann, M. P., Dubois, S. M., Agarwal, S., & Zon, L. I. (2021) · Disease Models & Mechanisms · doi:10.1242/dmm.048912 · Cited by 184
Lam, H. A., Wu, N., Cely, I., Kelly, R. L., Hean, S., Richter, F., Magen, I., Cepeda, C., Ackerson, L. C., Walwyn, W., et al. (2011) · Journal of Neuroscience Research · doi:10.1002/jnr.22611 · Cited by 184
“Increased striatal extracellular DA was also apparent in another model of PD, the parkin KO mouse (Goldberg et al., 2003), suggesting that increased extracellular DA may be a common mechanism contributing to substantia nigra DA neuron stress and eventual demise.”
BackgroundResultInfluentialSelf-citationSha, D., Chin, L.-S., & Li, L. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddp501 · Cited by 184
Genetic mouse models of Huntington's and Parkinson's diseases: illuminating but imperfect
Levine, M. S., Cepeda, C., Hickey, M. A., Fleming, S. M., & Chesselet, M.-F. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.08.008 · Cited by 183
Self-citationGenes, proteins, and neurotoxins involved in Parkinson’s disease
Halbach, O. V. B. U., Schober, A., & Krieglstein, K. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.002 · Cited by 181
Genetics and genomics of Parkinson’s disease
Lin, M. K., & Farrer, M. J. (2014) · Genome Medicine · doi:10.1186/gm566 · Cited by 179
“Traditionally, knockout mouse models of parkin, PINK1 or DJ-1 result in mitochondrial dysfunction [125] but do not develop the locomotor phenotype of parkinsonism, nigral neuronal loss or Lewy-body pathology; rather they have elevated dopaminergic tone due to deficits in D2 presynaptic regulation of release [126,127].”
BackgroundMono- and double-mutant mouse models of Parkinson's disease display severe mitochondrial damage
Stichel, C. C., Zhu, X.-R., Bader, V., Linnartz, B., Schmidt, S., & Lubbert, H. (2007) · Human Molecular Genetics · doi:10.1093/hmg/ddm083 · Cited by 179
“Only some a-synuclein transgenic lines showed morphological alterations in the dopaminergic system (43–45) and all generated Parkin-knockout lines lacked nigral degeneration [parkin-Ex3-Del (46,47); parkin– Ex2-Del (48); parkin-Ex7-Del (45)].”
BackgroundLu, X.-H., Fleming, S. M., Meurers, B., Ackerson, L. C., Mortazavi, F., Lo, V., Hernandez, D., Sulzer, D., Jackson, G. R., Maidment, N. T., et al. (2009) · The Journal of Neuroscience · doi:10.1523/jneurosci.5351-08.2009 · Cited by 178
“…parkin loss-offunction mutant mice do not exhibit the -synuclein pathology and DA neuron degeneration phenotypes observed in the ParkinQ311X mice (Goldberg et al., 2003; Itier et al., 2003; Lockhart et al., 2004; Palacino et al., 2004; von Coelln et al., 2004a; Fleming and Chesselet, 2005; Perez…”
BackgroundSelf-citationMandemakers, W., Morais, V. A., & De Strooper, B. (2007) · Journal of Cell Science · doi:10.1242/jcs.03443 · Cited by 176
“Intriguingly, parkin deficiency alone is not sufficient to cause neurodegeneration, which suggests additional unknown triggers are important for the disease process (Goldberg et al., 2003; Itier et al., 2003; Perez and Palmiter, 2005).”
BackgroundMitochondrial dysfunction in Parkinson's disease
Schapira, A. H. V. (2007) · Cell Death & Differentiation · doi:10.1038/sj.cdd.4402160 · Cited by 175
Synaptic dysfunction in progranulin-deficient mice
Petkau, T. L., Neal, S. J., Milnerwood, A., Mew, A., Hill, A. M., Orban, P., Gregg, J., Lu, G., Feldman, H. H., Mackenzie, I. R. A., et al. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.10.016 · Cited by 173
Neuroinflammation in Parkinson’s Disease
Lee, J.-K., Tran, T., & Tansey, M. G. (2009) · Journal of Neuroimmune Pharmacology · doi:10.1007/s11481-009-9176-0 · Cited by 171
Hu, Y., Li, X.-C., Wang, Z.-H., Luo, Y., Zhang, X., Liu, X.-P., Feng, Q., Wang, Q., Yue, Z., Chen, Z., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.7861 · Cited by 172
Genetic mouse models of parkinsonism: Strengths and limitations
Fleming, S. M., Fernagut, P.-O., & Chesselet, M.-F. (2005) · NeuroRX · doi:10.1602/neurorx.2.3.495 · Cited by 172
Self-citationHwang, D.-Y., Fleming, S. M., Ardayfio, P., Moran-Gates, T., Kim, H., Tarazi, F. I., Chesselet, M.-F., & Kim, K.-S. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3718-04.2005 · Cited by 171
“DOI:10.1523/JNEUROSCI.3718-04.2005 Copyright © 2005 Society for Neuroscience 0270-6474/05/252132-06$15.00/0 (Ogawa et al., 1985; Goldberg et al., 2003; Fleming et al., 2004; Fleming and Chesselet, 2005).”
BackgroundMethodInfluentialSelf-citationSensorimotor assessment of the unilateral 6-hydroxydopamine mouse model of Parkinson's disease
Glajch, K. E., Fleming, S. M., Surmeier, D. J., & Osten, P. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2011.12.007 · Cited by 168
Self-citationAssessment of Sensorimotor Function in Mouse Models of Parkinson's Disease
Fleming, S. M., Ekhator, O. R., & Ghisays, V. (2013) · Journal of Visualized Experiments · doi:10.3791/50303 · Cited by 166
Self-citationThe genetics of Parkinson disease: implications for neurological care
Klein, C., & Schlossmacher, M. G. (2006) · Nature Clinical Practice Neurology · doi:10.1038/ncpneuro0126 · Cited by 168
Targeting mitophagy in neurodegenerative diseases
Antico, O., Thompson, P. W., Hertz, N. T., Muqit, M. M. K., & Parton, L. E. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-024-01105-0 · Cited by 160
“However, a Parkin KO model displayed nor mal brain morphology with elevated striatal dopamine levels, reduced synaptic excitability in striatal neurons, and motor deficits on rotarod and beam tests 212 .”
Parkin and PINK1 functions in oxidative stress and neurodegeneration
Barodia, S. K., Creed, R. B., & Goldberg, M. S. (2017) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.12.004 · Cited by 167
“Rat Knockout Yes Yes ND1 Dave et al. 2014 PINK1 (PARK6) Drosophila Knockout Yes ND1 Park et al. 2006, Clark et al. 2006 Mouse Knockout No Yes Yes Kitada et al. 2007, Gautier et al. 2008, Gispert et al. 2009, Akundi et al. 2011.”
BackgroundResultSelf-citationAberrant protein S-nitrosylation contributes to the pathophysiology of neurodegenerative diseases
Nakamura, T., Prikhodko, O. A., Pirie, E., Nagar, S., Akhtar, M. W., Oh, C.-K., McKercher, S. R., Ambasudhan, R., Okamoto, S.-I., & Lipton, S. A. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2015.03.017 · Cited by 165
Biology of Mitochondria in Neurodegenerative Diseases
Martin, L. J. (2012) · Progress in Molecular Biology and Translational Science · doi:10.1016/b978-0-12-385883-2.00005-9 · Cited by 163
“Parkin null mice have a normal lifespan, do not develop any major neurological abnormalities, have no loss of midbrain dopaminergic neurons, and do not form intracellular inclusions.(255,256) However, these mice exhibit modest evidence of dopaminergic presynaptic dysfunction in striatum and possible deficits in behavi…”
Gene–environment interactions: Key to unraveling the mystery of Parkinson's disease
Gao, H.-M., & Hong, J.-S. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.03.005 · Cited by 165
Pathogenetic mechanisms of parkin in Parkinson's disease
Hattori, N., & Mizuno, Y. (2004) · The Lancet · doi:10.1016/s0140-6736(04)16901-8 · Cited by 162
Synaptic dysfunction in Parkinson's disease
Bagetta, V., Ghiglieri, V., Sgobio, C., Calabresi, P., & Picconi, B. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380493 · Cited by 160
Periquet, M., Corti, O., Jacquier, S., & Brice, A. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03442.x · Cited by 160
“We and others have recently generated a parkin knockout (KO) mouse model to facilitate investigation of the pathogenic mechanisms underlying parkinsonism due to parkin gene mutations (Goldberg et al. 2003; Itier et al. 2003; Von Coelln et al. 2004; Perez and Palmiter 2005).”
BackgroundMasoud, S. T., Vecchio, L. M., Bergeron, Y., Hossain, M. M., Nguyen, L. T., Bermejo, M. K., Kile, B., Sotnikova, T. D., Siesser, W. B., Gainetdinov, R. R., et al. (2015) · Neurobiology of Disease · doi:10.1016/j.nbd.2014.10.016 · Cited by 158
“Although genes such as PINK1, DJ1 and PARK2 (parkin) have been implicated in familial forms of PD, mutating or knocking-out these essential genes in most animal models does not reproduce dopaminergic cell loss (Gispert et al., 2009; Yamaguchi and Shen, 2007; Goldberg et al., 2003).”
BackgroundA tale on animal models of Parkinson's disease
Bezard, E., & Przedborski, S. (2011) · Movement Disorders · doi:10.1002/mds.23696 · Cited by 159
Animal models of the non-motor features of Parkinson's disease
McDowell, K., & Chesselet, M.-F. (2012) · Neurobiology of Disease · doi:10.1016/j.nbd.2011.12.040 · Cited by 156
Self-citationMitochondrial dysfunction within the synapses of substantia nigra neurons in Parkinson’s disease
Reeve, A. K., Grady, J. P., Cosgrave, E. M., Bennison, E., Chen, C., Hepplewhite, P. D., & Morris, C. M. (2018) · npj Parkinson's Disease · doi:10.1038/s41531-018-0044-6 · Cited by 152
Lonskaya, I., Hebron, M. L., Desforges, N. M., Schachter, J. B., & Moussa, C. E.-H. (2014) · Journal of Molecular Medicine · doi:10.1007/s00109-013-1112-3 · Cited by 152
“i lentiviral Aβ1–42 bilaterally into the hippocampus of 1-year-old male C57BL/6 (WT) or parkin mice (generated on a C57BL/6 background) [27], and 3 weeks later we injected 10 mg/kg nilotinib I.”
Mutant Parkin Impairs Mitochondrial Function and Morphology in Human Fibroblasts
Grünewald, A., Voges, L., Rakovic, A., Kasten, M., Vandebona, H., Hemmelmann, C., Lohmann, K., Orolicki, S., Ramirez, A., Schapira, A. H. V., et al. (2010) · PLoS ONE · doi:10.1371/journal.pone.0012962 · Cited by 152
“Similar results were obtained in additional animal models [6,7,8,9].”
ResultParkin and mitochondrial quality control: toward assembling the puzzle
Winklhofer, K. F. (2014) · Trends in Cell Biology · doi:10.1016/j.tcb.2014.01.001 · Cited by 166
Role of the ubiquitin proteasome system in Parkinson's disease
Lim, K.-L., & Tan, J. M. (2007) · BMC Biochemistry · doi:10.1186/1471-2091-8-s1-s13 · Cited by 151
“Indeed, with the exception of cell loss in the LC in a subsequent model generated by the Dawson laboratory (Johns Hopkins School of Medicine) [83], parkin null mice have generally failed to exhibit apparent signs of parkinsonism [81,82,84].”
BackgroundResultInfluentialSang, T.-K., Chang, H.-Y., Lawless, G. M., Ratnaparkhi, A., Mee, L., Ackerson, L. C., Maidment, N. T., Krantz, D. E., & Jackson, G. R. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.4810-06.2007 · Cited by 148
“…in locus ceruleus identified in parkin exon 7 knock-out mice reported by Dawson and coworkers (Von Coelln et al., 2004), a number of mouse genetic strategies have failed to recapitulate the neuronal cell death that is characteristic of PD (Goldberg et al., 2003; Perez and Palmiter, 2005).”
BackgroundSelf-citationα-Synuclein and Mitochondrial Dysfunction in Parkinson’s Disease
Mullin, S., & Schapira, A. (2013) · Molecular Neurobiology · doi:10.1007/s12035-013-8394-x · Cited by 146
“[130, 131]; however, reduced respiratory capacity and increased susceptability to oxidative damage which results in”
BackgroundMiro phosphorylation sites regulate Parkin recruitment and mitochondrial motility
Shlevkov, E., Kramer, T., Schapansky, J., LaVoie, M. J., & Schwarz, T. L. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1612283113 · Cited by 145
“To determine if S156E similarly altered mitochondrial behavior in neurons, we coexpressed Mito-DsRed to label mitochondria, synaptophysinGFP (Syp-GFP) to label axons, and either Myc-MiroWT or MycMiroS156E in either wild-type or Parkin KO mouse hippocampal neurons (48).”
BackgroundDrew, B. G., Ribas, V., Le, J. A., Henstridge, D. C., Phun, J., Zhou, Z., Soleymani, T., Daraei, P., Sitz, D., Vergnes, L., et al. (2014) · Diabetes · doi:10.2337/db13-0665 · Cited by 145
“Although mice with homozygous null mutation of Park2 (Parkin) show a less robust degeneration phenotype compared with Drosophila (54,55), Parkin mice were more susceptible to environmental and inflammation-induced neural degeneration than WT littermates (56).”
BackgroundLu, X., Altshuler-Keylin, S., Wang, Q., Chen, Y., Henrique Sponton, C., Ikeda, K., Maretich, P., Yoneshiro, T., & Kajimura, S. (2018) · Science Signaling · doi:10.1126/scisignal.aap8526 · Cited by 143
“Although genetic deletion of Park2 is insufficient to cause a Parkinson’s disease phenotype in mice (26, 27), Park2 knockout mice (referred to as Park2 KO mice) are resistant to body weight gain under a highfat diet, partially because of reduced lipid uptake by the fatty acid transporter CD36 (28, 29).”
BackgroundSchultheis, P. J., Fleming, S. M., Clippinger, A. K., Lewis, J., Tsunemi, T., Giasson, B., Dickson, D. W., Mazzulli, J. R., Bardgett, M. E., Haik, K. L., et al. (2013) · Human Molecular Genetics · doi:10.1093/hmg/ddt057 · Cited by 143
Self-citationMacroautophagy in CNS health and disease
Griffey, C. J., & Yamamoto, A. (2022) · Nature reviews. Neuroscience · doi:10.1038/s41583-022-00588-3 · Cited by 153
Malkus, K. A., Tsika, E., & Ischiropoulos, H. (2009) · Molecular Neurodegeneration · doi:10.1186/1750-1326-4-24 · Cited by 142
“nied by nigrostriatal defects, synaptic dysfunction, and dopaminergic behavioral deficits [138,142].”
BackgroundUbiquitin-proteasome-mediated local protein degradation and synaptic plasticity
Hegde, A. N. (2004) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2004.05.005 · Cited by 161
Glial Cells as Players in Parkinsonism: The “Good,” the “Bad,” and the “Mysterious” Glia
Mena, M. A., & García de Yébenes, J. (2008) · The Neuroscientist · doi:10.1177/1073858408322839 · Cited by 141
Keating, D. J. (2008) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04997.x · Cited by 141
Autophagy impairment in Parkinson’s disease
Karabiyik, C., Lee, M. J., & Rubinsztein, D. C. (2017) · Essays in Biochemistry · doi:10.1042/ebc20170023 · Cited by 140
Genetic mouse models of Parkinson’s disease
Magen, I., & Chesselet, M. (2010) · Progress in brain research · doi:10.1016/s0079-6123(10)84004-x · Cited by 156
Self-citationDegradation of engulfed mitochondria is rate-limiting in Optineurin-mediated mitophagy in neurons
Evans, C. S., & Holzbaur, E. L. (2020) · eLife · doi:10.7554/elife.50260 · Cited by 137
The PINK1/Parkin pathway: a mitochondrial quality control system?
Whitworth, A. J., & Pallanck, L. J. (2009) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-009-9253-3 · Cited by 137
“…of the PINK1 and parkin genes have mild phenotypes and do not recapitulate the dopamine neuron loss observed in humans, these mice do have nigrostriatal physiological defects suggesting a role for PINK1 and Parkin in dopamine neurotransmission (Goldberg et al. 2003; Kitada et al. 2007, 2009a, b).”
BackgroundSheng, D., Qu, D., Kwok, K. H. H., Ng, S. S., Lim, A. Y. M., Aw, S. S., Lee, C. W. H., Sung, W.-K. K., Tan, E. K., Lufkin, T., et al. (2010) · PLoS Genetics · doi:10.1371/journal.pgen.1000914 · Cited by 139
“In Parkin knockout mice, mutants with the deletion of exon2 [42] showed no abnormalities compared to wild-type mice in terms of the nigral DA neurons numbers and motor activity, while the mutants with the deletion of exon3 [43] showed behavioral deficits, but without DA neurons loss.”
BackgroundJoch, M., Ase, A. R., Chen, C. X.-Q., MacDonald, P. A., Kontogiannea, M., Corera, A. T., Brice, A., Séguéla, P., & Fon, E. A. (2007) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-11-1027 · Cited by 135
“Accordingly, defects in parkin-mediated ubiquitination have been proposed to result in the failure to target parkin substrates to the proteasome for degradation (Kahle et al., 2000; Feany and Pallanck, 2003; Giasson and Lee, 2003 ).”
BackgroundEkstrand, M. I., & Galter, D. (2009) · Parkinsonism & Related Disorders · doi:10.1016/s1353-8020(09)70811-9 · Cited by 155
“Knockout mice with deletion of parkin, Dj-1 or Pink1 genes have been generated [9–11] as have mice overexpressing mutant forms of human a-synuclein [12].”
BackgroundParkin-mediated ubiquitin signalling in aggresome formation and autophagy
Chin, L.-S., Olzmann, J. A., & Li, L. (2010) · Biochemical Society Transactions · doi:10.1042/bst0380144 · Cited by 134
“Parkin has been reported to regulate Lys48linked polyubiquitination and proteasomal degradation of several putative substrates [13,14], although the validity of these proteins as physiological parkin substrates remains controversial [16].”
BackgroundModels of α-synuclein aggregation in Parkinson’s disease
Giráldez-Pérez, R. M., Antolín-Vallespín, M., Muñoz, M. D., & Sánchez-Capelo, A. (2014) · Acta Neuropathologica Communications · doi:10.1186/s40478-014-0176-9 · Cited by 132
“Increased extracellular DA, decreased DAT, increased GSH levels and differences in the catabolism of DA have all been described in Parkin deficient mice [167-169].”
BackgroundHow does parkin ligate ubiquitin to Parkinson's disease?: First in Molecular Medicine Review Series
Kahle, P. J., & Haass, C. (2004) · EMBO reports · doi:10.1038/sj.embor.7400188 · Cited by 133
Parkin-associated Parkinson’s disease
von Coelln, R., Dawson, V. L., & Dawson, T. M. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0924-4 · Cited by 156
“Three parkin-deficient mice have been reported so far (Goldberg et al. 2003; Itier et al. 2003; von Coelln et al. 2004).”
BackgroundAnimal Models of Parkinson's Disease: Vertebrate Genetics
Lee, Y., Dawson, V. L., & Dawson, T. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a009324 · Cited by 132
“Many groups have generated parkin KO mice to model PD due to parkin loss (Goldberg et al. 2003; Itier et al. 2003; Von Coelln et al. 2004).”
BackgroundShaltouki, A., Sivapatham, R., Pei, Y., Gerencser, A. A., Momčilović, O., Rao, M. S., & Zeng, X. (2015) · Stem Cell Reports · doi:10.1016/j.stemcr.2015.02.019 · Cited by 130
“Likewise, similar mitochondrial defects exhibited in Park2 knockout (KO) mouse models, although only mice with conditional KO of Park2 recapitulate parkinsonian phenotype and striatonigral degeneration (Dawson et al., 2010; Goldberg et al., 2003).”
BackgroundOne-step generation of triple gene-targeted pigs using CRISPR/Cas9 system
Wang, X., Cao, C., Huang, J., Yao, J. T., Hai, T., Zheng, Q., Wang, X., Zhang, H., Qin, G., Cheng, J., et al. (2016) · Scientific Reports · doi:10.1038/srep20620 · Cited by 151
Pruning and loss of excitatory synapses by the parkin ubiquitin ligase
Helton, T. D., Otsuka, T., Lee, M.-C., Mu, Y., & Ehlers, M. D. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0802280105 · Cited by 129
“Interestingly, parkin-null mice show no abnormalities in gross brain morphology and no loss of dopaminergic neurons (23, 24, 40, 41).”
BackgroundDefective Autophagy in Parkinson’s Disease: Role of Oxidative Stress
Janda, E., Isidoro, C., Carresi, C., & Mollace, V. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8318-1 · Cited by 140
“In Parkin knockout mice, impaired mitochondrial function and decreased antioxidant capacity is accompanied by nigrostriatal defects, synaptic dysfunction, and dopaminergic behavioral deficits [84, 154].”
BackgroundMiller, S., & Muqit, M. M. K. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.04.029 · Cited by 129
“However, KO mice lacking PINK1 or Parkin genes show subtle behavioral and neurochemical abnormalities and no overt dopaminergic neuron degeneration [2,31,34,51,86] and therefore have been unable to address the contribution of PINK1 and Parkin to stress-evoked mitophagy in vivo.”
Doss-Pepe, E. W., Chen, L., & Madura, K. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413591200 · Cited by 129
Paterna, J.-C., Leng, A., Weber, E., Feldon, J., & Büeler, H. (2007) · Molecular Therapy · doi:10.1038/sj.mt.6300067 · Cited by 125
Impaired dopamine release and synaptic plasticity in the striatum of Parkin−/− mice
Kitada, T., Pisani, A., Karouani, M., Haburcak, M., Martella, G., Tscherter, A., Platania, P., Wu, B., Pothos, E. N., & Shen, J. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06152.x · Cited by 125
Self-citationPankratz, N., & Foroud, T. (2007) · Genetics in Medicine · doi:10.1097/gim.0b013e31815bf97c · Cited by 158
Drosophila models of neurodegenerative disease
Sang, T., & Jackson, G. R. (2005) · NeuroRx · doi:10.1602/neurorx.2.3.438 · Cited by 153
Role of Parkin and endurance training on mitochondrial turnover in skeletal muscle
Chen, C. C. W., Erlich, A. T., & Hood, D. A. (2018) · Skeletal Muscle · doi:10.1186/s13395-018-0157-y · Cited by 124
“The generation of these mice has been previously described [59].”
Alternative mitochondrial quality control mediated by extracellular release
Choong, C., Okuno, T., Ikenaka, K., Baba, K., Hayakawa, H., Koike, M., Yokota, M., Doi, J., Kakuda, K., Takeuchi, T., et al. (2020) · Autophagy · doi:10.1080/15548627.2020.1848130 · Cited by 124
“129S4-Park2tm1Shn/J), which model the exon 3 deletion mutation most common in human autosomal recessive juvenile parkinsonism patients, were purchased from Jackson Laboratories [41].”
BackgroundParkin Increases Dopamine Uptake by Enhancing the Cell Surface Expression of Dopamine Transporter
Jiang, H., Jiang, Q., & Feng, J. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m409282200 · Cited by 122
Coque, L., Mukherjee, S., Cao, J.-L., Spencer, S., Marvin, M., Falcon, E., Sidor, M. M., Birnbaum, S. G., Graham, A., Neve, R. L., et al. (2011) · Neuropsychopharmacology · doi:10.1038/npp.2011.33 · Cited by 120
“Nucleus accumbens (NAc) dopamine measurements were performed as described previously (Goldberg et al, 2003).”
MethodSelf-citationKitao, Y., Imai, Y., Ozawa, K., Kataoka, A., Ikeda, T., Soda, M., Nakimawa, K., Kiyama, H., Stern, D. M., Hori, O., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl439 · Cited by 119
“Parkin homozygous mutant mice were born at the expected mendelian ratio, showed no overt abnormalities (except a slight decrease in body weight) and had normal lifespans (18,19).”
BackgroundParkin Protects against Neurotoxicity in the 6-Hydroxydopamine Rat Model for Parkinson's Disease
Vercammen, L., der Perren, A. V., Vaudano, E., Gijsbers, R., Debyser, Z., den Haute, C. V., & Baekelandt, V. (2006) · Molecular Therapy · doi:10.1016/j.ymthe.2006.06.009 · Cited by 130
“Surprisingly, genetic inactivation of the parkin gene in mice [19–22] and Drosophila [23,24] failed to reproduce the typical dopaminergic cell loss, although more recently shrinkage and degeneration of a subset of dopaminergic neurons were detected in Drosophila parkin mutants [25,26].”
BackgroundEtiology and Pathogenesis of Parkinson Disease
Schapira, A. H. V. (2009) · Neurologic Clinics · doi:10.1016/j.ncl.2009.04.004 · Cited by 150
Metadata
- Authors
- Goldberg, M. S., Fleming, S. M., Palacino, J. J., Cepeda, C., Lam, H. A., Bhatnagar, A., Meloni, E. G., Wu, N., Ackerson, L. C., Klapstein, G. J., Gajendiran, M., Roth, B. L., Chesselet, M.-F., Maidment, N. T., Levine, M. S., & Shen, J.
- Affiliations
- Brigham and Women's Hospital (US)
- University of California, Los Angeles (US)
- Case Western Reserve University (US)
- Corresponding author
- Shen, Jie
- ORCID
- Venue
- Journal of Biological Chemistry
- Publisher
- Elsevier BV
- Published
- 2003-10
- Volume
- 278
- Issue
- 44
- Pages
- 43628-43635
- ISSN
- 0021-9258 (ISSN-L)
- OpenAlex
- W2088962120
- Cited by
- 913
- References
- 72
- Citations by year
- 2026: 8 · 2025: 25 · 2024: 35 · 2023: 27 · 2022: 45 · 2021: 39 · 2020: 39 · 2019: 25 · 2018: 39 · 2017: 40 · 2016: 29 · 2015: 34 · 2014: 41 · 2013: 43 · 2012: 36
- FWCI
- 33.13
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- www.elsevier.com/tdm/userlicense/1.0/ (tdm)
- creativecommons.org/licenses/by/4.0/ (vor, 6206 d)
- Locations
- Journal of Biological Chemistry (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Keywords
- Parkin, Parkinson's disease, nigrostriatal pathway, dopaminergic neurons, substantia nigra, striatum, dopaminergic modulation, synaptic excitability, spiny neurons, E3 ubiquitin ligase, alpha-synuclein, synphilin-1, neuronal survival
- MeSH terms
- Alleles, Animals, Behavior, Animal, Brain, Chromatography, High Pressure Liquid, Disease Models, Animal, Dopamine, Electrophysiology, Mice, Transgenic, Models, Genetic, Neurons, Parkinson Disease, Receptors, Dopamine, Substantia Nigra, Time Factors, Blotting, Western, Germ-Line Mutation, Ubiquitin-Protein Ligases, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.